Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 2/2014

01-02-2014 | Adis Drug Evaluation

Afatinib: A Review of Its Use in the Treatment of Advanced Non-Small Cell Lung Cancer

Author: Gillian M. Keating

Published in: Drugs | Issue 2/2014

Login to get access

Abstract

Afatinib (Gilotrif™, Giotrif®) is an orally administered, irreversible inhibitor of the ErbB family of tyrosine kinases. Afatinib downregulates ErbB signalling by covalently binding to the kinase domains of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor (HER) 2 and HER4, resulting in irreversible inhibition of tyrosine kinase autophosphorylation; it also inhibits transphosphorylation of HER3. Afatinib is approved as monotherapy for the treatment of EGFR tyrosine kinase inhibitor (TKI)-naïve adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutations in the EU, and for the first-line treatment of patients with metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test in the US. In two randomized, open-label, multinational phase III trials, progression-free survival was significantly prolonged with afatinib compared with pemetrexed plus cisplatin (LUX-Lung 3) or gemcitabine plus cisplatin (LUX-Lung 6) in treatment-naïve patients with advanced NSCLC with activating EGFR mutations. The objective response rate was significantly higher with afatinib than with pemetrexed plus cisplatin or gemcitabine plus cisplatin, and patient-reported outcomes for symptoms such as cough and dyspnoea and certain health-related quality of life measures significantly favoured afatinib versus pemetrexed plus cisplatin or gemcitabine plus cisplatin. Afatinib also showed efficacy in EGFR TKI-naïve patients with advanced lung adenocarcinoma and activating EGFR mutations who had received no more than one prior chemotherapy regimen for advanced disease, according to the results of the noncomparative, multinational, phase II LUX-Lung 2 trial. Oral afatinib had a manageable tolerability profile. EGFR-mediated adverse events (e.g. diarrhoea, rash/acne) were generally managed using dose reduction and delays. In conclusion, afatinib is a valuable new option for use in treatment-naïve or EGFR TKI-naïve patients with advanced lung adenocarcinoma and activating EGFR mutations.
Literature
1.
Liao B-C, Lin C-C, Yang JC-H. First-line management of EGFR-mutated advanced lung adenocarcinoma: recent developments. Drugs. 2013;73(4):357–69.PubMedCrossRef
2.
Bonanno L, Favaretto A, Rugge M. Role of genotyping in non-small cell lung cancer treatment: current status. Drugs. 2011;71(17):2231–46.PubMedCrossRef
3.
4.
Metro G, Crinò L. The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer. Expert Rev Anticancer Ther. 2011;11(5):673–82.PubMedCrossRef
5.
Hirsh V. Afatinib (BIBW 2992) development in non-small-cell lung cancer. Future Oncol. 2011;7(7):817–25.PubMedCrossRef
6.
Nelson V, Ziehr J, Agulnik M, et al. Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC. Onco Targets Ther. 2013;6:135–43.PubMedCentralPubMed
7.
Bordoni RE. Afatinib (BIBW-2992): a novel dual EGFR/HER2neu inhibitor with promising activity in non-small-cell lung cancer. Therapy. 2011;8(1):15–22.CrossRef
8.
Brugger W, Thomas M. EGFR-TKI resistant non-small cell lung cancer (NSCLC): new developments and implications for future treatment. Lung Cancer. 2012;77(1):2–8.PubMedCrossRef
9.
10.
11.
12.
QIAGEN N.V. QIAGEN submits companion diagnostic to FDA to guide treatment decisions for new investigational lung cancer compound [media release]. 2013. http://​www.​qiagen.​com. Accessed 23 Oct 2013.
13.
QIAGEN N.V. QIAGEN receives FDA approval for therascreen® EGFR RGQ PCR Kit as a companion diagnostic for lung cancer patients [media release]. 2013. http://​www.​qiagen.​com. Accessed 23 Oct 2013.
14.
Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008;27(34):4702–11.PubMedCentralPubMedCrossRef
15.
Solca F, Dahl G, Zoephel A, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther. 2012;343(2):342–50.PubMedCrossRef
16.
Chen G, Kronenberger P, Teugels E, et al. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. BMC Med. 2012;10:28.PubMedCentralPubMedCrossRef
17.
Takezawa K, Okamoto I, Tanizaki J, et al. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor. Mol Cancer Ther. 2010;9(6):1647–56.PubMedCrossRef
18.
Furuyama K, Harada T, Iwama E, et al. Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors. Cancer Sci. 2013;104(5):584–9.PubMedCrossRef
19.
Ninomiya T, Takigawa N, Ichihara E, et al. Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model. Mol Cancer Ther. 2013;12(5):589–97.PubMedCrossRef
20.
Kim Y, Ko J, Cui Z-Y, et al. The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor. Mol Cancer Ther. 2012;11(3):784–91.PubMedCrossRef
21.
Regales L, Gong Y, Shen R, et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest. 2009;119(10):3000–10.PubMedCentralPubMed
22.
Kim SM, Kwon O-J, Hong YK, et al. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation. Mol Cancer Ther. 2012;11(10):2254–64.PubMedCrossRef
23.
Chen G, Noor A, Kronenberger P, et al. Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib. PLoS One. 2013;8(3):e59708.PubMedCentralPubMedCrossRef
24.
Molife LR, Rudman SM, Alam S, et al. Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors. Cancer Chemother Pharmacol. 2013;72(6):1213–22.PubMedCrossRef
25.
Eskens FALM, Mom CH, Planting AST, et al. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer. 2008;98(1):80–5.PubMedCentralPubMedCrossRef
26.
Marshall J, Hwang J, Eskens FALM, et al. A phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors. Invest New Drugs. 2013;31(2):399–408.PubMedCentralPubMedCrossRef
27.
Yap TA, Vidal L, Adam J, et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol. 2010;28(25):3965–72.PubMedCrossRef
28.
Gordon MS, Mendelson DS, Gross M, et al. A phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors. Invest New Drugs. 2013;31(2):409–16.PubMedCentralPubMedCrossRef
29.
Kristeleit H, Puglisi M, Middleton GW, et al. Phase II, open-label trial to assess the effect of continuous oral afatinib (BIBW 2992) at a daily dose of 50 mg on QTc, pharmacokinetics, and efficacy in relapsed or refractory solid tumors including brain metastases and glioblastoma that is not amenable to other therapy [abstract no. 2613]. J Clin Oncol. 2011;29(15 Suppl 1).
30.
Wind S, Schmid M, Erhardt J, et al. Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours. Clin Pharmacokinet. 2013;52(12):1101–9.PubMedCrossRef
31.
Sequist LV, Yang JC-H, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327–34.PubMedCrossRef
32.
Stopfer P, Marzin K, Narjes H, et al. Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers. Cancer Chemother Pharmacol. 2012;69(4):1051–61.PubMedCrossRef
33.
Agus DB, Terlizzi E, Stopfer P, et al. A phase I dose escalation study of BIBW 2992, and irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumours [abstract]. J Clin Oncol. 2006;24(18S):2074.
34.
Yang JC-H, Shih J-Y, Su W-C, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. 2012;13(5):539–48.PubMedCrossRef
35.
Wu YL, Zhou C, Hu C-P, et al. LUX-Lung 6: a randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung [abstract no. 8016]. J Clin Oncol. 2013;31(15 Suppl) (plus poster presented at the 49th Annual Meeting of the American Society of Clinical Oncology; 31 May-4 Jun 2013; Chicago (IL)).
36.
Yang JC-H, Hirsh V, Schuler M, et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3342–50.PubMedCrossRef
37.
Geater SL, Zhou C, Hu C-P, et al. LUX-Lung 6: patient-reported outcomes (PROs) from a randomized open-label, phase III study in first-line advanced NSCLC patients (pts) harboring epidermal growth factor receptor (EGFR) mutations [abstract no. 8061]. J Clin Oncol. 2013;31(15 Suppl) (plus poster presented at the 49th Annual Meeting of the American Society of Clinical Oncology; 31 May–4 Jun 2013; Chicago (IL)).
38.
Yang JC, Schuler M, Yamamoto N, et al. Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations in LUX-Lung 3, a phase III trial of afatinib or cisplatin/pemetrexed in EGFR mutation-positive lung cancer [abstract no. 1252P]. Ann Oncol. 2012;23(Suppl 9):ix410–1.
39.
Yang JC-H, Sequist LV, Geater SL, et al. Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations: findings from three trials of afatinib in EGFR mutation-positive lung cancer [abstract no. O03.05 plus slide presentation]. 15th World Conference on Lung Cancer; 27–30 Oct 2013; Sydney.
40.
Mok T, Schuler M, Yamamoto N, et al. LUX-Lung 3: afatinib vs. cisplatin and pemetrexed in Asian patients with adenocarcinoma of the lung harbouring an epidermal growth factor receptor mutation [abstract no. HO-003]. 5th Asia Pacific Lung Cancer Conference; 26–28 Nov 2012; Fukuoka.
41.
Yamamoto N, Schuler M, O’Byrne K, et al. LUX-Lung 3: afatinib vs. cisplatin and pemetrexed in Japanese patients with adenocarcinoma of the lung harbouring an EGFR mutation [abstract no. PLS-6]. Ann Oncol. 2012;23(Suppl 11):xi8.
42.
Schuler M, Yang JC-H, Sequist LV, et al. Efficacy of afatinib vs. chemotherapy in treatment-naïve patients with non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations with or without metastatic brain disease [abstract no. MO07.13 plus slide presentation]. 15th World Conference on Lung Cancer; 27–30 Oct 2013; Sydney.
43.
Yang JC-H, Sequist LV, O’Byrne KJ, et al. Epidermal growth factor receptor (EGFR)-mediated adverse events in patients with EGFR mutation-positive non-small cell lung cancer (NSCLC) treated with afatinib [abstract no. 895]. Eur J Cancer. 2013;49(Suppl 2):S190 (plus poster presented at European Cancer Congress 2013; 27 Sep–1 Oct 2013; Amsterdam).
44.
Yang JC-H, Reguart N, Barinoff J, et al. Diarrhea associated with afatinib: an oral ErbB family blocker. Expert Rev Anticancer Ther. 2013;13(6):729–36.PubMedCrossRef
45.
Lacouture ME, Schadendorf D, Chu C-YC, et al. Dermatologic adverse events associated with afatinib: an oral ErbB family blocker. Expert Rev Anticancer Ther. 2013;13(6):721–8.PubMedCrossRef
46.
Goss G, Lu S, Felip E, et al. LUX-Lung 8: a randomized, open-label, phase III trial of afatinib vs. erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-based chemotherapy [abstract no. 509TiP]. Ann Oncol. 2012;23(Suppl 9):ix174.
47.
Boehringer Ingelheim Pharmaceuticals. LUX-Lung 8: a phase III trial of afatinib (BIBW 2992) versus erlotinib for the treatment of squamous cell lung cancer after at least one prior platinum based chemotherapy [ClinicalTrials.gov identifier NCT01523587]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://​www.​clinicaltrials.​gov/​ct2/​show/​NCT01523587. Accessed 21 Oct 2013.
48.
Boehringer Ingelheim Pharmaceuticals. LUX-Lung 7: a phase IIb trial of afatinib (BIBW2992) versus gefitinib for the treatment of 1st line EGFR mutation positive adenocarcinoma of the lung [ClinicalTrials.gov identifier NCT01466660]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://​www.​clinicaltrials.​gov/​ct2/​show/​NCT01466660. Accessed 21 Oct 2013.
49.
Chen X, Zhu Q, Zhu L, et al. Clinical perspective of afatinib in non-small cell lung cancer. Lung Cancer. 2013;81(2):155–61.PubMedCrossRef
50.
Janjigian YY, Smit EF, Horn L, et al. Activity of afatinib/cetuximab in patients (pts) with EGFR mutant non-small cell lung cancer (NSCLC) and acquired resistance (AR) to EGFR inhibitors [abstract no. 12270]. Ann Oncol. 2012;23(Suppl 9):ix401.
51.
52.
Langer CJ. Epidermal growth factor receptor inhibition in mutation-positive non-small-cell lung cancer: is afatinib better or simply newer? J Clin Oncol. 2013;31(27):3303–6.PubMedCrossRef
53.
De Grevè J, Teugels E, Geers C, et al. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer. 2012;76(1):123–7.PubMedCrossRef
54.
55.
Boehringer Ingelheim Pharmaceuticals. LUX-Breast 3; afatinib alone or in combination with vinorelbine in patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer suffering from brain metastases [ClinicalTrials.gov identifier NCT01441596]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://​www.​clinicaltrials.​gov/​ct2/​show/​NCT01441596. Accessed 23 Oct 2013.
56.
Boehringer Ingelheim Pharmaceuticals. LUX-Head&Neck 1: a phase III trial of afatinib (BIBW2992) versus methotrexate for the treatment of recurrent and/or metastatic (R/M) head and neck squamous cell cancer after platinum based chemotherapy [ClinicalTrials.gov identifier NCT01345682]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://​www.​clinicaltrials.​gov/​ct2/​show/​NCT01345682. Accessed 23 Oct 2013.
57.
Boehringer Ingelheim Pharmaceuticals. LUX-Head&Neck 2: a phase III trial of afatinib (BIBW 2992) versus placebo for the treatment of head and neck squamous cell cancer after treatment with chemo-radiotherapy [ClinicalTrials.gov identifier NCT01345669]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://​www.​clinicaltrials.​gov/​ct2/​show/​NCT01345669. Accessed 23 Oct 2013.
58.
Boehringer Ingelheim Pharmaceuticals. LUX-Head&Neck 3: afatinib (BIBW2992) versus methotrexate for the treatment of recurrent and/or metastatic head and neck squamous cell cancer after platinum based chemotherapy [ClinicalTrials.gov identifier NCT01856478]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://​www.​clinicaltrials.​gov/​ct2/​show/​NCT01856478. Accessed 23 Oct 2013.
Metadata
Title
Afatinib: A Review of Its Use in the Treatment of Advanced Non-Small Cell Lung Cancer
Author
Gillian M. Keating
Publication date
01-02-2014
Publisher
Springer International Publishing
Published in
Drugs / Issue 2/2014
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-013-0170-8

Other articles of this Issue 2/2014

Drugs 2/2014 Go to the issue

Review Article

Acute Hyperglycemia Associated with Short-Term Use of Atypical Antipsychotic Medications

Current Opinion

Responsiveness to Erythropoiesis-Stimulating Agents in Chronic Kidney Disease: Does Geography Matter?

R&D Insight Report

Sofosbuvir: First Global Approval

R&D Insight Report

Ibrutinib: First Global Approval

Adis Drug Evaluation

Rivaroxaban: A Review of Its Use in the Treatment of Deep Vein Thrombosis or Pulmonary Embolism and the Prevention of Recurrent Venous Thromboembolism

Adis Drug Evaluation

Sitagliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus